CST Expands Partnership with Bio-Rad
Complete the form below to unlock access to ALL audio articles.
Cell Signaling Technology, Inc. (CST), has announced that it has entered into a new partnership agreement with Bio-Rad Laboratories, Inc.
Under the agreement, CST will develop antibodies for kinase activation and protein phosphorylation assays that will be commercialized in Bio-Rad's multiplex bead-based assays for the Bio-Plex® suspension array system.
CST's scientific and technical expertise will be leveraged to develop a broader array of antibodies for Bio-Rad's Bio-Plex® platform, enabling multiplexed measurement of phosphoproteins and signaling pathways.
Bio-Plex® phosphoprotein assays are optimized for simultaneous assessment of kinase and signaling protein activation states and provide critical tools for disease research and drug development.
Given the complexity of cellular signaling and the diversity of mechanistic abnormalities underlying disease, Bio-Plex® multiplexed phosphoprotein assays can facilitate the understanding of disease and the development of more effective targeted therapeutic strategies.
"Our partnership with Bio-Rad in the past has enabled CST to combine our antibody expertise with Bio-Rad's strength in multiplexed assay technologies," said Christopher Bunker, CST's Director of Business Development.
"Bio-Plex phosphoprotein assays built with CST antibody content provide the means for rigorous parallel analysis of signal transduction pathways."
"Advances in cellular signaling research will have a great impact both in our understanding of fundamental biological processes and in advancing the treatment of disease," said Bio-Rad Vice President and Group Manager, Life Science Group, Brad Crutchfield.
"Together, CST and Bio-Rad can provide more quickly a broader array of tools for kinase and signal transduction research."
